Gary N. Schwartz, M.D.
Associate Professor of Medicine
Stanford University, BA 1979Stanford University School of Medicine, MD 1985
Norris Cotton Cancer Center
Dartmouth Medical School
Hanover NH 03755
Office: Rubin Building-Room 519
Assistant: Nadine Lunt
Asst. Phone: 603-650-8898
Cancer chemotherapy and endocrine therapy for breast cancer, signal transduction pathways in breast cancer, and new drug development.
ZD1839 (Iressa) in Tamoxifen-Resistant Metastatic Breast Cancer, Principal Investigator, (NCI-NIH)
S14 as a Therapeutic Targetin Breast Cancer, Co-investigator, (DOD)
Pendyala L. Schwartz G. Smith P. Zdanowicz J. Murphy M. Hausheer F Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy. Cancer Chemotherapy & Pharmacology. 51(5):376-84, 2003 May (view details on MedLine)
Schwartz GN, Pendyala L, Kindler H, Meropol N, Perez R, Raghavan D, and Creaven P The clinical development of paclitaxel and the paclitaxel/carboplatin combination. Eur J Cancer 34(10):1543-1548, 1998 (view details on MedLine)
Schwartz GN, Teicher BA, Eder JP, Korbut T, Holden SA, Ara G, Herman TS Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine. Cancer Chemotherapy and Pharmacology, 1993, 32:455-62 (view details on MedLine)